

# **OPEN ACCESS**

APPROVED BY

Frontiers Editorial Office, Frontiers Media SA, Lausanne, Switzerland

\*CORRESPONDENCE

Frontiers Production Office production.office@frontiersin.org

RECEIVED 05 September 2024 ACCEPTED 05 September 2024 PUBLISHED 25 October 2024

### CITATION

Frontiers Production Office (2024) Erratum: Addressing chemically-induced obesogenic metabolic disruption: selection of chemicals for *in vitro* human PPAR $\alpha$ , PPAR $\gamma$  transactivation, and adipogenesis test methods. *Front. Endocrinol.* 15:1491855. doi: 10.3389/fendo.2024.1491855

### COPYRIGHT

© 2024 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Erratum: Addressing chemically-induced obesogenic metabolic disruption: selection of chemicals for *in vitro* human PPAR $\alpha$ , PPAR $\gamma$ transactivation, and adipogenesis test methods

# Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

adipogenesis, obesogen, peroxisome proliferator-activated receptor, metabolic disruption, integrated testing strategy, test guideline, validation

# An Erratum on

Addressing chemically-induced obesogenic metabolic disruption: selection of chemicals for *in vitro* human PPAR $\alpha$ , PPAR $\gamma$  transactivation, and adipogenesis test methods

By Ozcagli E, Kubickova B and Jacobs MN (2024). Front. Endocrinol. 15:1401120. doi: 10.3389/fendo.2024.1401120

Due to a production error, there was a mistake in Tables 2A-C as published. The molecular structures were incorrectly placed in these tables. The corrected Tables 2A-C appear below.

The publisher apologizes for this mistake.

The original version of this article has been updated.

TABLE 2A  $\,$  Selected chemicals and activity bands for the PPAR  $\!\alpha$  assay.

Chemical	Cas No.	Structure	Use	hPPARα ag/antag ● inactive ○	
Negative					
Bisphenol A (BPA)	80-05-7	но	Plasticiser, industrial chemical	0	
Triphenylphosphate (TPP)	115-86-6	O-0-P-0-	Industrial chemical	0	
Dichlorodiphenyldichloroethylene (pp²-DDE)	72-55-9	CI CI	Pesticide metabolite (Stockholm POPs list)	0	
Triclosan (TCS)	3380-34-5	CI CI CI	Bacteriocide	0	
Rosiglitazone (ROSI)	122320-73-4	*	Pharmaceutical	0	
Chlorpyrifos (CPF)	2921-88-2	CI CI CH <sub>3</sub>	Organophosphate pesticide	0	
Perfluorohexanoic acid (PFHXA)	307-24-4	F F F OOH	Breakdown product of PFAS	0	
(aR)-4-chloro-a-[3-(trifluoromethyl)phenoxy] benzeneacetic acid, (MBX-102/JNJ39659100) Arhalofenate MBX-102	24136-23-0	F <sub>3</sub> C OH	Experimental pharmaceutical	0	
Tetrabrominated BPA (TBBPA)	79-94-7	Br H <sub>3</sub> C CH <sub>3</sub> Br HO H	Flame retardant	O -/?	
LGD1069 (Targretin) Bexarotene	153559-49-0	ООН	Pharmaceutical	0	
Weak activity		1			
Phytanic acid	14721-66-5	CH <sub>5</sub> CH <sub>5</sub> CH <sub>5</sub> CH <sub>5</sub> CH <sub>6</sub> CH <sub>6</sub> CH <sub>6</sub> CH <sub>7</sub>	Dietary lipid	+ Very weak agonist 10 <sup>-4</sup> μM	
Clofibrate	637-07-0	CI H <sub>3</sub> C CH <sub>3</sub> CH <sub>3</sub>	Pharmaceutical, fibrate	+ Weak-moderate agonist up to 10 <sup>-4</sup> μM	
AGN194204 (IRX4204)	220619-73-8	ОН	Pharmaceutical	Weak antagonist	
Weak to moderate activity					
Mono-(2-Ethylhexyl) Phthalate (MEHP)	4376-20-9	OH CH <sub>0</sub>	Phthalate, plasticiser	+ Moderate agonist	

(Continued)

TABLE 2A Continued

Chemical	Cas No.	Structure	Use	hPPARα ag/antag ● inactive ○	
Weak to moderate activity					
Eicosapentaenoic acid (EPA)	10417-94-4	ОСН	Nutrient, long chain PUFA essential fatty acid	+ Moderate agonist	
Tesaglitazar/AZ242	251565-85-2	** Company	Pharmaceutical	+ Selective moderate agonist 3 μM	
Clofibric acid	882-09-7	ОН	Herbicide and pharmaceutical; active metabolite of clofibrate	+ Moderate agonist (EC <sub>50</sub> = 50.0 μM)	
Strong activity					
Perfluorooctanoic acid (PFOA)	335-67-1	F F F F F O	Industrial chemical, non- stick coating	+ Strong agonist	
Pristanic acid	1189-37-3		Dietary lipid	+ Strong agonist 1 μM	
Docosahexaenoic acid (DHA)	6217-54-5		Nutrient, long chain PUFA essential fatty acid	+ Strong agonist	
Positive control					
GW7647	265129-71-3		Pharmaceutical candidate	+ Selective agonist, positive control 10 nM	

TABLE 2B Selected chemicals and activity bands for the PPAR $\gamma$  assay.

Chemical	Cas No.	Structure	Use	hPPARγ ag/ antag ● inactive ○
Negative				
Bisphenol A (BPA)	80-05-7	но	Plasticiser, industrial chemical	0
Dichlorodiphenyldichloroethylene (pp'-DDE)	72-55-9	CI CI	Pesticide metabolite (Stockholm POPs list)	0
Triclosan (TCS)	3380-34-5	CI OH CI	Bacteriocide	0
Perfluorohexanoic acid (PFHXA)	307-24-4	OH FFFFFF	Breakdown product of PFAS	0

(Continued)

TABLE 2B Continued

Chemical	Cas No.	Structure	Use	hPPARγ ag/ antag <b>●</b> inactive ○
Negative				
LGD1069 (Targretin) Bexarotene	153559-49-0	Š, ooh	Pharmaceutical	0
Weak activity				
Chlorpyrifos (CPF)	2921-88-2	CI CI CH <sub>1</sub>	Organophosphate pesticide	+ Weak agonist
Clofibrate	637-07-0	O CH <sub>3</sub>	Pharmaceutical, fibrate	+ Weak- moderate agonist
Phytanic acid	14721-66-5	Ch Ch Ch Ch C	Dietary lipid	+ Weak- moderate agonist
(aR)-4-chloro-a-[3-(trifluoromethyl)phenoxy] benzeneacetic acid, (MBX-102/JNJ39659100) Arhalofenate MBX-102	24136-23-0		Experimental pharmaceutical	+ Weak agonist
GW3965 hydrochloride	405911-17-3	GF5 O HG	Pharmaceutical candidate	+ Weak agonist
Weak to moderate activity				
Mono-(2-Ethylhexyl) Phthalate (MEHP)	4376-20-9	O CH <sub>0</sub>	Phthalate, plasticiser	+ Moderate agonist
GW7647	265129-71-3	S COOH	Pharmaceutical candidate	+ Moderate agonist
Eicosapentaenoic acid (EPA)	10417-94-4	О ОН СН <sub>3</sub>	Nutrient, long chain PUFA essential fatty acid	+ Moderate agonist
Clofibric acid	882-09-7	CI OH OH	Herbicide and pharmaceutical; active metabolite of clofibrate	+ Weak-Moderate agonist (but weaker than PPARα)
Pristanic acid	1189-37-3		Dietary lipid	+ Weak-moderate agonist 10 μM

(Continued)

TABLE 2B Continued

Chemical	Cas No.	Structure	Use	hPPARγ ag/ antag <b>●</b> inactive ○	
Strong activity					
Triphenyl phosphate (TPP)	115-86-6	0-0-F-0-()	Industrial chemical: Adhesives and sealants, coating products, cosmetics and personal care products	+ Strong agonist	
Docosahexaenoic acid (DHA)	6217-54-5		Nutrient, long chain PUFA essential fatty acid	+ Strong agonist	
Tetrabrominated BPA (TBBPA)	79-94-7	Br H <sub>1</sub> G CH <sub>3</sub> Br HO H	Flame retardant	+ Strong agonist	
Perfluorooctanoic acid (PFOA)	335-67-1	F F F F F O	Industrial chemical, non- stick coating	+ Strong agonist	
15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)	87893-55-8	CH <sub>3</sub> (CH <sub>2</sub> ) <sub>3</sub> CH <sub>2</sub>	Metabolite of endogenous prostaglandin (PGJ2)	+ Strong agonist	
Tesaglitazar/ AZ 242	251565-85-2	H <sub>1</sub> C - 9 OH OH OH	Pharmaceutical	+ Strong agonist 40 nM	
Positive control					
Rosiglitazone (ROSI)	122320-73-4		Pharmaceutical	+ Positive control	

 ${\sf TABLE~2C~Selected~chemicals~and~activity~bands~for~the~hMSC~adipogenesis~assay}.$ 

Chemical	Cas No.	Structure	Use	hMSC adipogenesis (lipid accumulation) ag/antag € inactive ○
Negative				
Triclosan (TCS)	3380-34-5	CI OH CI	Bacteriocide	0
TTNPB, 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl] benzoic acid, Arotinoid acid	71441-28-6	H <sub>5</sub> C OH <sub>5</sub> CH <sub>5</sub> COH	Pharmaceutical	Strong inhibitor of adipogenesis; unlike retinoic acids (9cRA) that promotes adipogenesis

(Continued)

# TABLE 2C Continued

Chemical	Cas No.	Structure	Use	hMSC adipogenesis (lipid accumulation) ag/antag ● inactive ○	
Negative					
Dichlorodiphenyldichloroethylene (pp³-DDE)	72-55-9	CI CI	Pesticide metabolite (Stockholm POPs list)	?-	
Chlorpyrifos (CPF)	2921-88-2	CI CI S CH <sub>3</sub>	Organophosphate pesticide	0	
Weak activity					
Perfluorooctanoic acid (PFOA)	335-67-1	F F F F F F CH	Industrial chemical, non- stick coating	+ Weak inducer	
Weak to moderate activity					
GW3965 hydrochloride	405911-17-3	GF <sub>0</sub> ·HCl	Pharmaceutical candidate	+ Weak/ moderate inducer	
Tetrabrominated BPA (TBBPA)	79-94-7	Br H <sub>2</sub> C <sub>C</sub> CH <sub>3</sub> Br HO Br GH	Flame retardant	+Moderate inducer 10 µM induced adipogenesis in 3T3- L1 cells	
Mono-(2-Ethylhexyl) Phthalate (MEHP)	4376-20-9	OH CH <sub>3</sub>	Phthalate, plasticiser	+ Moderate 10 µM and was maximal at 100 µM	
Triphenyl phosphate (TPP)	115-86-6	⊘-o-g-o-√>	Industrial chemical: Adhesives and sealants, coating products, cosmetics and personal care products	+ Agonist at high dose (>1μM)	
Strong activity					
Fludioxonil	131341-86-1	F CN	Non-systemic fungicide	+ Strong (significant at 0.2 µM)	
Tributyltin (TBT) chloride	1461-22-9	H <sub>5</sub> C CH <sub>5</sub>	Fungicide	+ Strong inducer adipogenic differentiation (3T3-L1)	
Positive control					
Rosiglitazone (ROSI)	122320-73-4		Pharmaceutical	+ Positive control	